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Abstract
Background:  Skeletal muscle atrophy can occur under many different conditions, including
prolonged disuse or immobilization, cachexia, cushingoid conditions, secondary to surgery, or with
advanced age. The mechanisms by which unloading of muscle is sensed and translated into signals
controlling tissue reduction remains a major question in the field of musculoskeletal research.
While the fibroblast growth factors (FGFs) and their receptors are synthesized by, and intimately
involved in, embryonic skeletal muscle growth and repair, their role maintaining adult muscle status
has not been examined.
Methods: We examined the effects of ectopic expression of FGFR1 during disuse-mediated
skeletal muscle atrophy, utilizing hindlimb suspension and DNA electroporation in mice.
Results: We found skeletal muscle FGF4 and FGFR1 mRNA expression to be modified by hind
limb suspension,. In addition, we found FGFR1 protein localized in muscle fibers within atrophying
mouse muscle which appeared to be resistant to atrophy. Electroporation and ectopic expression
of FGFR1 significantly inhibited the decrease in muscle fiber area within skeletal muscles of mice
undergoing suspension induced muscle atrophy. Ectopic FGFR1 expression in muscle also
significantly stimulated protein synthesis in muscle fibers, and increased protein degradation in
weight bearing muscle fibers.
Conclusion: These results support the theory that FGF signaling can play a role in regulation of
postnatal skeletal muscle maintenance, and could offer potentially novel and efficient therapeutic
options for attenuating muscle atrophy during aging, illness and spaceflight.
Background
Skeletal muscle atrophy can occur under many different
conditions, including prolonged disuse or immobiliza-
tion, cachexia, cushingoid conditions, secondary to sur-
gery, or with advanced age. Atrophy is characterized by
decreases in muscle mass, muscle mass to body ratio [1,2],
and myofiber cross-sectional area [3]. Additional changes
noted in atrophied skeletal muscle are a decrease in over-
all nucleic acid quantities, as well as a loss of myonuclei
[4]. These physical characteristics are accompanied by
decreased muscle strength [5], and increased propensity
to muscle fatigue [6]. If severe enough, these changes can
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significantly impact the quality of life and productivity of
an individual.
The mechanisms by which unloading of muscle is sensed
and translated into signals controlling tissue reduction
remains a major question in the field of musculoskeletal
research. Two ubiquitin ligases have been identified that
are involved with initiating approximately 50% of skeletal
muscle atrophy associated with denervation [7]. However,
there are currently no universally effective treatments
available for skeletal muscle atrophy during disuse. Sev-
eral strategies have been used in an attempt to attenuate
or reverse muscle atrophy associated with disuse. The suc-
cess of these attempts appears to depend on the action of
growth factors used, the delivery system employed, and
the model of atrophy studied. For example, intra-muscu-
lar injection of IGF-I protein inhibited muscle atrophy
associated with denervation [8] and electroporation of
IGF-I expression plasmid inhibited muscle loss associated
with hind limb suspension [9], while administration of
GH and/or IGF-I did not attenuate muscle atrophy associ-
ated with hind limb suspension [10]. Exercise was
required in addition to administration of GH and IGF-I in
order to inhibit muscle degeneration associated with dis-
use atrophy [10]. However, in certain clinical situations
such as bed-ridden or casted patients, exercise is not an
option when attempting to attenuate muscle atrophy.
The fibroblast growth factors (FGFs) have been shown to
be intimately involved in fetal skeletal muscle growth and
development and development of cultured skeletal mus-
cle in vitro. FGFs are strong regulators of myoblast prolif-
eration in vitro [11-17]. FGF expression and synthesis is
localized to developing skeletal muscle masses in vivo, and
in muscle cultures in vitro [18-27]. In these masses, FGF
and FGFR expression is associated with the proliferative
myoblast state [28]. In vitro, FGFR1, FGF1, FGF2, FGF6
and FGF7 are expressed in proliferating cultures of MM14
skeletal muscle precursor cells, and down-regulated upon
differentiation [29]. Because of these expression patterns
and regulatory effects mentioned above in skeletal muscle
in vitro, it was believed classically that FGFs were respon-
sible for stimulating proliferation of myogenic precursor
cells in vivo. While this may be true for some FGFs, it is
becoming clearer that not all FGF-family members will
have a proliferation stimulating/differentiation inhibiting
function with regard to skeletal muscle development in
vivo. FGF5 and FGF4 significantly inhibit the development
of differentiated skeletal muscle myofibers, without any
significant stimulatory effect on myoblast proliferation in
vivo [28,30].
The role of the FGF-family in regulation of postnatal skel-
etal muscle growth and maintenance is less clear. Expres-
sion of FGF-1 and 2 is significantly increased in the
muscle fibers of facioscapulohumeral muscular dystrophy
(FSHD) [31]. Electrically stimulated rat muscles showed a
threefold increase of the mRNA levels of both FGF-1 and
FGF-2 [32], indicating release during exercise and possible
roles in the response of skeletal muscle to work. In addi-
tion to the changes seen in expression under various phys-
iological conditions, FGF-2 can aid in muscle healing in
vivo. Application of exogenous FGF-2 to injured muscle
increased the number of regenerating fibers and the twitch
and tetanus strength of muscle as compared to control
muscles [33]. Injection of FGF-2 into the muscle of mdx
mice increases the number of regenerating myofibers and
this effect is positively correlated to the quantity of FGF-2
injected [34]. Physical trauma of skeletal muscle in FGF-6
null mice results in an inhibition of the healing process,
and extensive fibrosis and myotube degeneration. When
mdx mice were crossed with FGF-6 null mice the resultant
offspring showed severe myopathies. These included
myotube necrosis and large amounts of fibrosis, indicat-
ing inhibition of muscle regeneration [35].
The FGFs exert their biological effects on cells via both
high affinity tyrosine kinase (FGFRs) and low affinity
heparan sulfate proteoglycan (HSPGs) cell surface recep-
tors [36]. In adult skeletal muscle, the two main FGFRs
expressed are FGFR1 and FGFR4 [36]. FGFR1 is proposed
to be a receptor for several members of the FGF family,
and is believed to be associated with cellular proliferation.
In electrically stimulated muscle, expression of FGFR1 was
isolated to skeletal muscle fibers, and is doubled over
non-stimulated muscles [32]. FGFR-4 expression is signif-
icantly increased in the connective tissue of facioscapulo-
humeral muscular dystrophy (a form of muscular
dystrophy) [31].
While evidence is beginning to accumulate that FGFs will
be involved in postnatal muscle maintenance and growth,
their exact role has yet to be completely elucidated. In this
manuscript, we examined FGFR1 expression during dis-
use-mediated skeletal muscle atrophy. We found FGFR1
to be expressed in muscle fibers within atrophying mus-
cle, fibers which appeared to be resistant to atrophy. We
also found that ectopic expression of FGFR1 within skele-
tal muscle fibers inhibited disuse mediated muscle atro-
phy. In muscles of suspended animals, FGFR1
overexpression stimulated protein synthesis. These results
support the theory that FGFR1 plays a role in regulation of
postnatal skeletal muscle maintenance, conserving a pop-
ulation of fibers which could be potentially used for
mobility during times of stress. These results could offer
potentially novel and efficient therapeutic options for
attenuating muscle atrophy during aging, illness and
spaceflight.BMC Musculoskeletal Disorders 2007, 8:32 http://www.biomedcentral.com/1471-2474/8/32
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Methods
Hindlimb suspension
All experimental procedures involving mice were per-
formed in accordance with guidelines set forth by the Pur-
due Animal Care and Use Committee. Hindlimb
suspension (HS) was performed on mice using the tail
cast model established by Morey et al. [37] and modified
by Park and Schultz [38]. Mice were attached to a two-
dimensional track system by their tails. This modification
allows mice free access to food and water ad libitum, but
prevents mice from placing a load on their hind limbs.
Twelve-week-old male mice (AKR/J, Jackson Labs, Bar
Harbor, ME) were weighed and randomly assigned to
either HS for 4 d (n = 12), for 7 d (n = 11), or kept in nor-
mal weight bearing/non-suspension (NS, n = 12) state.
After suspension, body weights were recorded, mice were
euthanized and muscle samples were collected. Gastroc-
nemius muscles were weighed, snap frozen in 2-methylb-
utane cooled in liquid nitrogen, and stored at -80°C for
histological analysis. Frozen cross-sections 10 μm were
cut at -23°C using a Microm HM500 Cryostat (Walldorf,
Germany) and subbed to silane-coated slides.
In situ hybridization
Sense and anti-sense RNA probes were generated using
the full-length coding sequence for FGF-4 cloned into
Bluescript (Stratagene, La Jolla, California) [24], forming
a template for a MAXIScript in-vitro transcription
(Ambion, Austin, TX) using a [33P] UTP label. FGFR1
probes were generated using reverse transcription proto-
cols and PCR primers as described [40]. Briefly, cDNA
templates for PCR were generated by reverse transcribing
total RNA from mouse muscle. FGFR1 cDNA was ampli-
fied using the following forward and reverse primers:
(AGAGACCAGCTGTGATGA) and (AATACGACTCAC-
TATAGGGTGAGGAAGACAGAGTCCTCC), respectively,
where the reverse primer contained the T7 promoter
sequence. FGFR1 cDNA was electrophoresed and purified
using the QIAquick Gel Extraction Kit (Qiagen, Valencia,
CA). Purified FGFR1 cDNA was used as a template with
the aforementioned MAXIScript in-vitro transcription
(Ambion, Austin, TX) and [33P] UTP to generate ribo-
probes for in situ hybridization as outlined previously.
Control probes were generated using either labeled sense
probes or excess cold antisense RNA probes as described
[41].
In situ hybridization was performed as described previ-
ously [40]. Briefly, sections were fixed with 4% (w/v)
paraformaldehyde in 1 × phosphate buffered saline (PBS)
for 20 min and rinsed twice for 5 min in 1 × PBS. Sections
were overlaid with proteinase K solution (20 μg/ml pro-
teinase K diluted in 50 mM Tris-HCl, 5 mM EDTA; pH
8.0) for 5 min and washed in 1 × PBS for 5 min. Sections
were post-fixed as described previously in the 4% (w/v)
paraformaldehyde solution. Slides were acetylated for 10
min using triethanolamine/acetic anhydride at pH 8.0.
Sections were washed in 1 × PBS, dehydrated using abso-
lute ethanol and air dried. Labeled probes were added to
hybridization solution (4 × SSC, 1 × Denhardt's, 16 μg
tRNA, 10% dextran sulfate, 50% formamide) at a final
concentration of 50,000 cpm/μl. Sections were incubated
overnight at 55°C. Following hybridization, sections were
washed once for 15 min and twice for 30 min in wash
solution (50% formamide in 2 × SSC at 65°C) and twice
for 60 min in 35% formamide, 1 × SSC, 0.5 × PBS at 65°C.
Three muscle sections from 10 animals from each treat-
ment (control, 4 days hind limb suspension, and 7 days
of hind limb suspension) were analyzed. Following
hybridization, slides were subjected to a phosphor screen
(Packard BioScience, Meriden, CT) overnight. Images
were acquired using the Cyclone Storage Phosphor Sys-
tem (Packard BioScience, Meriden, CT), and analyzed
using the Optiquant image analysis software provided
with the system (Packard BioScience, Meriden, CT).
Immunohistochemistry
Muscle cross-sections were blocked for 5 min at room
temperature in a solution containing 0.3% horse serum
(v/v) and 0.3% hydrogen peroxide (v/v) diluted in 1 ×
phosphate buffered saline (PBS). After blocking, sections
were washed in 1 × PBS. The mouse-on-mouse immu-
noglobulin blocking solution (Vector M.O.M Immunode-
tection Kit; Vector Laboratories, Inc., Burlingame, CA) was
used. Sections were blocked 1 h at room temperature in
the mouse-on-mouse blocking solution. Slides were
rinsed in 1 × PBS and incubated 5 min with the mouse-
on-mouse working solution. Excess solution was removed
and sections were incubated for 30 min with a mouse
monoclonal FGFR1 antibody (QED Bioscience, San
Diego, CA) diluted 1:2000 in working solution, or anti α-
Actinin (Sigma-Aldrich, St. Louis, MO) diluted 1:800.
Slides were rinsed in 1 × PBS and incubated 10 min at
room temperature with biotinylated anti-mouse IgG. Sec-
tions were rinsed in 1 × PBS and exposed to an avidin-
biotin-horseradish peroxidase complex (ABComplex®
Elite Kit; Vector Laboratories, Inc. Burlingame, CA). Slides
were rinsed with 1 × PBS and reacted with 3,3'-diami-
nobenzidine substrate. Slides were washed in 1 × PBS,
dried and coverslipped. Slides stained by immunohisto-
chemistry for analysis were of muscle sections from the
middle region of the muscle. Digital images were captured
with a Leaf Microlumina camera (Scitex, Tel-Aviv, Israel)
mounted on an Olympus BX50 microscope (Olympus,
Melville, NY). Sections stained with anti α-Actinin were
scanned at 20 × magnification and used to measure cross-
sectional area of muscle fibers. A total of 16 fields were
scanned from both legs from each mouse. From each field
10 randomly selected fibers were outlined using AdobeBMC Musculoskeletal Disorders 2007, 8:32 http://www.biomedcentral.com/1471-2474/8/32
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Photoshop© (Adobe Systems, Inc., San Jose, CA) to deter-
mine cross-sectional area using the histogram function. A
total of 800 myofibers were examined in the gastrocne-
mius from mice which had undergone 7 days of hindlimb
suspension, while 960 fibers the gastrocnemius were
examined from mice which had undergone 4 days of
hindlimb suspension, and from control mice.
DNA constructs
A full length cDNA encoding FGFR1 cloned into the MIRB
expression vector was kindly provided by D.M. Ornitz
(Washington University, St. Louis, MO). Plasmid DNA
containing the full coding region of FGF-4 cloned into
Bluescript (Stratagene, La Jolla, California) was provided
by Lee Niswander (University of Colorado, Denver, CO).
Control pcDNA 3.1 (+) plasmid DNA was purchased from
Invitrogen (catalog no. V790-20, Carlsbad, CA). Cytome-
galovirus (CMV)-Lac-Z encoding β-galatosidase was pro-
vided by B.B. Olwin (University of Colorado, Boulder,
CO). Renilla luciferase vector containing the SV40 pro-
moter region (pRL-SV40) was purchased from Promega
(catalog no. E2231, Madison, WI). Plasmid DNA encod-
ing for Runx2/Osf2 under the control of a cytomegalovi-
rus promoter (pCMV-Osf2) and mouse osteocalcin gene 2
(mOG2) promoter fused to a luciferase reporter (pII 1.5
Luc) were gifts from R.T. Franceschi (University of Michi-
gan, Ann Arbor, MI). Plasmid DNA encoding an ubiqui-
tin-tagged luciferase (Ub-Fl) was a gift from D. Piwnica-
Worms (Washington University, St. Louis). All DNA plas-
mids for animal injections were purified using Endo Free
Plasmid Maxi Kits from Qiagen (catalog no. 12362,
Valencia, CA).
In-Vivo plasmid DNA transfection
Plasmid DNA was electroporated into skeletal muscle fib-
ers of twelve-week-old ND4 male mice (Harlan, Indiana-
polis, IN) as described previously [42]. Mice were
anesthetized using an intraperitoneal injection cocktail
containing ketamine (9 mg/ml) and xylazine (1 mg/ml)
in 0.9% saline at 0.01 ml/gram body weight. Hind limbs
were shaved and the gastrocnemius and soleus muscles
were injected with 50 μl of a 0.9% saline solution contain-
ing either 30 μg FGFR1 plasmid DNA and β-galactosidase
(20 μg), or control plasmid (30 μg) and β-galactosidase
(20 μg) in the contralateral limb through the skin. After
DNA injection, electrotransfer gel was applied to each
limb, and two plate electrodes connected to an ECM 830
electrical pulse stimulator (BTX® inc., Holliston, MA) were
positioned on the lateral and medial aspects of the leg
adjacent to the muscle. Limbs were pulsed 8 times at 200
V/cm, 20 msec/pulse with a delay of 1 sec between pulses.
Forty-eight hours after electroporation, mice were ran-
domly assigned to either HS for 7 d (n = 6), HS for 14 d
(n = 6), or a reloaded treatment (n = 6). For the reloaded
treatment, mice were suspended for 7 d, and then allowed
to recover in a non-suspended, weight bearing status for 7
d. Following treatments, mice were euthanized and mus-
cle samples were collected and frozen as described previ-
ously.
Gastrocnemius muscles were sectioned and stained for β-
galactosidase [43]. Briefly, sections were fixed in 0.5% glu-
teraldehyde for 5 min at room temperature and rinsed in
1 × PBS. Sections were incubated in the dark overnight at
37°C in a solution containing 1 mg/ml X-Gal (5-bromo-
4-chloro-3-indolyl-β D-galactopyranosidase; BP1615-1,
Fisher Scientific, Fair Lawn, NJ), 10 mM K-ferricyanide, 10
mM K-ferrocyanide and 0.2 mM MgCl2, diluted in 1 ×
PBS. After color development, sections were rinsed in 1 ×
PBS and coverslipped. Images were captured with Scion
Image for Windows Beta 4.0.2 (Scion Corporation, Fred-
erick, MD) using a Nikon DN100 digital camera (Nikon
Corporation, Tokyo, Japan) mounted on a Nikon Lab-
phot light microscope (Nikon Corporation, Tokyo,
Japan). Cross-sectional area of at least thirty β-galactosi-
dase positive myofibers/per section/per animal were
determined using Adobe Photoshop (Adobe Systems,
Inc., San Jose, CA). Ten sections/animals were analyzed.
This experiment was performed three times.
Downstream detection of FGF signaling
Gastrocnemius and soleus muscles of mice were electro-
porated as described with 50 μl of a 0.9% saline solution
containing 30 μg of plasmid DNA encoding FGFR1, a
Runx2 expression plasmid (20 μg), a mOG2-luciferase
reporter gene (20 μg) and CMV-renilla luciferase (10 μg).
Contralateral control limbs received 30 μg of control plas-
mid DNA, Runx2 expression plasmid (20 μg), mOG2-
luciferase reporter gene (20 μg) and renilla luciferase (20
μg). Five days after transfection mice were euthanized,
and gastrocnemius muscle samples were frozen in liquid
nitrogen. Muscle samples were powdered in a mortar and
pestle cooled in liquid nitrogen and homogenized in pas-
sive lysis buffer (PLB) (catalog no. E1941, Promega, Mad-
ison, WI) containing leupeptin (2.1 μM/L), aprotinin,
(0.15 μM/L), and phenylmethylsulfonyl fluoride (10 μM/
L). Luciferase activity in each muscle sample was deter-
mined using the Dual-Luciferase® Reporter Assay System
(catalog no. E1960, Promega, Madison, WI), measured on
a TD-20/20 luminometer (Turner Designs, Sunnyvale,
CA). Luciferase activity of mOG2 was normalized to
renilla luciferase activity in each sample to correct for
transfection efficiency.
Protein synthesis
ND4 male mice (Harlan, Indianapolis, IN) were electro-
porated into the gastrocnemius/soleus muscle, as
described above, with 100 μg FGFR1 plasmid DNA. The
contralateral muscle then received 100 μg of control plas-BMC Musculoskeletal Disorders 2007, 8:32 http://www.biomedcentral.com/1471-2474/8/32
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mid DNA. Mice were randomly assigned to either HS
treatment (n = 9) for 10 d, or normal weight bearing treat-
ment for 10 d (n = 10). DNA transfections and HS were
performed as previously outlined. To determine protein
synthesis, a modification the flooding dose method
described [44] was performed. Briefly, 250 μCi L-[4-3H]
phenylalanine (catalog no. TRK204, Amersham, Piscata-
way, NJ) per mouse and 150 μmol unlabeled phenyla-
lanine/100 g body weight was administered
intraperitoneally. Thirty min after dosing, mice were euth-
anized, hindlimbs were skinned, and placed on ice for dis-
section. Gastrocnemius and soleus muscles were
removed, snap frozen in liquid nitrogen and stored at -
80°C for later analysis.
Frozen samples were powdered using a mortar and pestle
cooled in liquid nitrogen and homogenized in PLB as
described previously. Protein concentration of the
homogenate was determined using the bicinchoninic acid
protein assay (catalog no. 23225, Pierce, Rockford, IL). A
volume containing 200 μg of total protein was precipi-
tated in one quarter volume 0.2 M perchloric acid (PCA)
and pelleted. Pellets were washed twice with 0.2 M PCA
and solubilized using 0.5 ml of 0.5 M NaOH. Solubilized
pellets were added to 10 ml EcoLite™(+) scintillation fluid
(catalog no. 882475, ICN Biomedicals, Inc., Irvine, CA)
and counted using liquid scintillation (Model B1600,
Packard BioScience, Meriden, CT). This experiment was
performed three times.
Proteasome activity
Proteasome activity was assayed using the ubiquitin-luci-
ferase reporter as described by Luker et al [45]. Gastrocne-
mius and soleus muscles of 12-week-old ND4 male mice
(Harlan, Indianapolis, IN) were electroporated with a
0.9% saline solution containing either 30 μg FGFR1, Ub-
Fl (20 μg), and renilla luciferase (10 μg), or control (30
μg), Ub-Fl (20 μg), and renilla luciferase (10 μg) plasmid
DNAs. The ubiquinated luciferase construct synthesizes a
ubiquitin-luciferase fusion protein that is degraded by,
and an indicator or activity of, the ATP-depended proteo-
some. Mice were randomly assigned to either HS treat-
ment (n = 5) for 10 d, or remained in weight bearing
treatment (n = 4) for 10 d. At the conclusion of the treat-
ment period, mice were euthanized, muscles were col-
lected and processed as described previously for
determining firefly and renilla luciferase activity.
Statistical analysis
To test the effect of FGFR1 treatment and hindlimb
unloading on muscle fiber area (CSA), tritium incorpora-
tion, and proteasome activity, a general linear model of
SAS was used to perform the analysis of variance. A mixed
model with mouse as a blocking factor for repeated meas-
ures analysis was performed on contralateral limbs as
repeated measurements within each mouse. The data
from the protein synthesis study showed a poisson distri-
bution, so data were transformed (square root). Probabil-
ity values less than 0.05 were considered statistically
different.
Results
Muscle morphology
In comparison to the weight bearing controls, after 7 days
of hindlimb suspension fiber CSA was significantly
decreased in the gastrocnemius by an average of 311 μm2
(control : 1688 μm2; 4 days of hind limb suspension :
1454 μm2; 7 days of hind limb suspension : 1277 μm2;
SEM = 52 μm2; all means significantly different p < .05).
In-situ hybridization
Quantitative in-situ hybridization of the gastrocnemius
using probes for FGFR1 and FGF-4 demonstrated detecta-
ble levels of growth factor expression in control animals.
Hind limb suspension significantly altered the expression
of FGFR1 and FGF4 after 4 and 7 days when compared
with weight bearing controls. Following 4 days of disuse
FGFR1 mRNA expression was significantly increased, with
expression levels at 178% of controls (p < 0.05). After 7
days of disuse FGFR1 mRNA expression was significantly
decreased, with expression at only 66% of controls (p <
0.05; Figure 1.A,B). FGF-4 mRNA levels were significantly
elevated after 4 days of hind limb suspension at 192% of
control (p < 0.01; Figure 1.A,C). After 7 days of disuse
FGF-4 expression was still significantly elevated when
compared to controls (145% of control; p < 0.01; Figure
1.A,C), but was significantly lower than expression levels
noted after 4 days of disuse (p < 0.01; Figure 1.A,C). Con-
trol sense ribroprobes did not yield significant hybridiza-
tion signal (data not shown).
FGFR1 immunohistochemistry
A population of fibers immunostained strongly positive
for FGFR1 in gastrocnemius muscles from mice following
7 days of disuse atrophy (Figure 2.A,B). This localized
increase in FGFR1 immunoreactivity was not detected in
control muscle. The average CSA of fibers expressing
increased levels of FGFR1 protein in atrophied muscle was
significantly larger than fibers not demonstrating this
increase (in atrophied muscle) by 522 μm2 (p < 0.01; Fig-
ure 2.C). The average diameter of the FGFR1 expressing
fibers in atrophying muscle (1615 μm2) was similar to
that of the weight bearing controls (1688 μm2).
Overexpression of FGFR1 in muscle blunts muscle atrophy
To determine if the elevated FGFR1 was playing a direct
role in maintaining muscle fiber size during disuse atro-
phy, muscle fibers were electroporated with an FGFR1
expression plasmid and subjected to HS. After 7 d HS, fib-
ers expressing electroporated FGFR1 were 17% larger (P <BMC Musculoskeletal Disorders 2007, 8:32 http://www.biomedcentral.com/1471-2474/8/32
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FGFR1 and FGF4 mRNAs are up-regulated in muscle undergoing disuse atrophy Figure 1
FGFR1 and FGF4 mRNAs are up-regulated in muscle undergoing disuse atrophy. FGFR1 and FGF4 mRNAs were 
analyzed in sections of gastrocnemius muscle obtained from control mice or mice suspended for 4 or 7 days by in situ hybridi-
zation. In comparison to controls, FGFR1 and FGF4 mRNA signal, as depicted by white silver grains in dark field images, were 
upregulated in gastrocnemius muscles suspended for 4 days (A). Direct dpm analyses were obtained using the Cyclone Storage 
Phosphor System, and FGFR1 and FGF4 mRNA levels were found to be significantly greater in muscles suspended for 4 days 
than control muscle or muscle suspended for 7 days. Dotted lines represent the outline of the gastrocnemius muscles. SEM 
indicated over control; means with different superscripts differ p < .05; n = 10 for each mean.
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FGFR1 protein is up-regulated in muscle fibers during disuse atrophy Figure 2
FGFR1 protein is up-regulated in muscle fibers during disuse atrophy. FGFR1 was immunolocalized in sections of 
gastrocnemius muscle obtained from control mice or mice suspended for 7 days. In comparison to the control gastrocnemius 
(A), FGFR1 protein, as depicted by the brown precipitate (black arrows), was increased in atrophying muscle (B). In sections of 
the gastrocnemius isolated from suspended mice, the area of the FGFR1-positive muscle fibers was significantly greater than 
the FGFR1 negative fibers (C). The area of the FGFR1 positive myofibers in the atrophying muscle was the same as the area of 
control myofibers (1688 mm2). This data suggests that FGFR1 acts to inhibit fiber atrophy associated with disuse. ** indicates 
p < .01; SEM indicated; bar represents 50 mm.
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0.05) than those fibers from the contralateral control
limbs expressing a control plasmid. Similarly, fibers
expressing electroporated FGFR1 in mice suspended 14 d
were 62% larger (P < 0.01) than fibers from the contralat-
eral control limbs expressing a control plasmid. In
reloaded animals, muscle fibers expressing electroporated
FGFR1 were 24% larger (P < 0.01) than contralateral con-
trol muscle fibers expressing control plasmid (Figures 3
and 4). These results demonstrate that FGFR1 plays an
active role in inhibiting the loss in muscle fiber diameter
that occurs during unloading. No significant difference
was noted in the CSA of fibers transfected with FGFR1 and
LacZ when compared with fibers transfected with only
LacZ in the muscles of weight bearing mice (LacZ express-
ing fibers: 1623 μm; FGFR1/LacZ expressing fibers: 1615
μm; SEM = 323).
FGFR1 in muscle regulates protein synthesis and 
degradation
To determine the effects of FGFR1 on protein turnover,
protein synthesis and protein degradation were evaluated
in FGFR1 electroporated muscles. Gastrocnemius/soleus
muscles from mice subjected to HS for 10 d incorporated
less (P < 0.05) tritium than those of unsuspended mice
(Figure 5). These results confirm previous studies that
demonstrate a reduction of protein synthesis that occurs
during hind limb suspension [46]. In both weight bearing
and suspended gastrocnemius/soleus muscles electropo-
rated with FGFR1, there was an average 16% greater (P <
0.05) tritium incorporated than in contralateral muscles
electroporated with control plasmid (Figure 5). These
results show that ectopic expression of FGFR1 stimulates
protein synthesis in skeletal muscle fibers in vivo.
The 26S proteasome represents a key component in ubiq-
uitin-mediated proteolysis, so activity of the proteasome
was used to determine the regulation of proteolysis by
FGFR1. The proteasome reporter plasmid encodes a poly-
ubiquitinated sequence linked to luciferase [45]. Higher
luciferase activity indicates lower proteasomal activity,
and thus interpreted as lower proteolysis. Proteasome
activity was significantly (P < 0.01) increased 2.3 fold in
muscles from control, suspended muscle as compared to
muscles isolated from weight bearing control mice. This
data is in agreement with previous studies showing prote-
olysis is increased in muscle undergoing hind limb sus-
pension induced-atrophy [45]. Proteasome activity of
muscles from suspended mice electroporated with FGFR1
Overexpression of FGFR1 inhibits muscle atrophy Figure 4
Overexpression of FGFR1 inhibits muscle atrophy. 
Cross-sectional area (CSA) of fibers from gastrocnemius 
muscles of mice transfected with either control (control) or 
FGFR1 expression plasmid DNA (FGFR1), subjected to hind-
limb suspension for 7 d (7 d HS), 14 d (14 d HS), reloaded for 
7 d after 7 d of hindlimb suspension (7 d reloaded), or non-
suspended controls (NS). Means (±SEM) bearing different let-
ters differ significantly (P < 0.05).
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Ectopic expression of FGFR1 inhibits atrophy Figure 3
Ectopic expression of FGFR1 inhibits atrophy. β-galac-
tosidase expression in muscle fibers from gastrocnemius 
muscles of mice co-transfected with a β-galactosidase 
expression vector and either a control (control) or FGFR1 
expression plasmid DNA (FGFR1). Rows represent fibers 
from muscles of mice suspended for 7 d (7 d HS), 14 d (14 d 
HS), or reloaded for 7 d after 7 d HS (reloaded). The bar in 
the bottom right figure represents 50 μm.
7 d HS
14 d HS
Reloaded
Control FGFR1
50 µmBMC Musculoskeletal Disorders 2007, 8:32 http://www.biomedcentral.com/1471-2474/8/32
Page 9 of 12
(page number not for citation purposes)
was not significantly different from contra-lateral muscles
electroporated with control plasmid. In muscle from
weight-bearing control mice electroporated with FGFR1,
there was a 2.5 fold increase (P < 0.01) in proteosome
activity (Figure 6) as compared to the contralateral muscle
electroporated with control plasmid.
Downstream detection of FGF signaling in muscle
As described previously [9], we sometimes have difficulty
using immunohistochemistry to display ectopic plasmid
protein expression. Although we used muscles that
showed no overt necrosis and mineralization in response
to electroporation, there still seemed to be an insult to the
muscle that appeared as a strong affinity for the secondary
antibody during immunohistochemistry. Even on sec-
tions from muscles 30 days post-electroporation, there
was a strong background of secondary antibody immu-
nostaining, that we could not block with MOM kits
(Mouse On Mouse, Vector Laboratories) or excess
quenching with unlabeled secondary antibodies. There-
fore, to verify FGF signaling was stimulated by overexpres-
sion of FGFR1, a reporter assay using plasmid DNAs for
Runx2 and mOG2-luciferase as described by Xiao et al.
[47] was utilized. FGF signaling is required for Runx2
phosphorylation, which is required for activation of OG2
transcription. Increased mOG2 reporter gene activity is
indicative of increased FGF-signaling. Gastrocnemius and
soleus muscles electroporated with FGFR1 plasmid DNA
exhibited a two-fold increase (P < 0.05) in OG2 luciferase
activity as compared to control muscles electroporated
with control plasmid (Figure 7). These results verify that
FGF-signaling was stimulated by ectopic expression of
FGFR1.
Discussion
FGFs are demonstrated regulators embryonic skeletal
muscle growth and repair. However, their importance
Downstream detection of activated FGF signaling Figure 7
Downstream detection of activated FGF signaling. 
Activity of mouse osteocalcin gene 2 promoter (mOG2)-luci-
ferase reporter gene in gastrocnemius and soleus muscles of 
mice transfected with either control (control) or FGFR1 
expression plasmid DNA (FGFR1). Data are expressed as 
luciferase dependent light units normalized to renilla luci-
ferase dependent light units (mOG2/Fl). Means (±SEM) bear-
ing different letters differ significantly (P < 0.01).
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Overexpression of skeletal muscle with FGFR1 increases  protein synthesis Figure 5
Overexpression of skeletal muscle with FGFR1 
increases protein synthesis. Incorporation of L-[4-3H] 
phenylalanine in gastrocnemius and soleus muscles of weight 
bearing or hindlimb suspended mice transfected with control 
(control) or FGFR1 expression plasmid DNA (FGFR1). Val-
ues represent back transformation of means (+SE/-SE) gener-
ated using a square root transformation. Values bearing 
different letters differ significantly (P < 0.05).
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Proteasome activity is unaffected by overexpression of  FGFR1 in muscle subjected to hindlimb suspension (HS) Figure 6
Proteasome activity is unaffected by overexpression 
of FGFR1 in muscle subjected to hindlimb suspension 
(HS). Luminescence of extracts from the gastrocnemius and 
soleus muscles of mice transfected with either control (con-
trol) or FGFR1 expression plasmid DNA (FGFR1), subjected 
to either hindlimb suspension (HS), or non-suspended con-
trols (NS). Data are expressed as luciferase dependent light 
units of Ub-Fl normalized to renilla luciferase dependent light 
units. Means (±SEM) bearing different letters differ signifi-
cantly (P < 0.05).
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during adult muscle maintenance in vivo has not been
examined. In this manuscript, we found FGFR1 to be syn-
thesized in a population of muscle fibers within atrophy-
ing muscle which appeared to be resistant to reduced
load. We also found that ectopic expression of FGFR1
within skeletal muscle fibers in vivo inhibited disuse
mediated muscle atrophy through a mechanism that
included stimulation of protein synthesis. In muscle fibers
bearing a load, we found ectopic FGFR1 stimulates pro-
tein synthesis and degradation.
FGFRs have been implicated in regulation of myoblast
proliferation and differentiation [48], but an FGFR role in
fiber maintenance post-differentiation has not been
widely reported. The position of FGFR1 as a cell surface
receptor places it in a position where it may affect many
cellular processes, as well as the response of an individual
fiber to the surrounding micro-environment. The elevated
expression noted in individual myofibers could indicate
that increased FGFR1 confers some form of protection
from atrophy by increasing the sensitivity of the myofiber
to whatever soluble growth factors are present. Our work
demonstrated that there was a concurrent increase in
expression of at least one ligand in atrophying muscle,
FGF4. Significant increases in FGF4 expression have been
previously noted in a model of skeletal muscle hypertro-
phy [49], but have not been previously reported in any
models of disuse or atrophy.
Our results would indicate FGFR1 has a role in maintain-
ing postnatal muscle fiber size and strength in a specific
population of myofibers during periods of disuse. When
a muscle undergoes atrophy during reduced load such as
the hind limb suspension model, proteins are degraded
into amino acids via the ATP-dependent proteosome [7].
These amino acids can then converted into glucose by the
liver and then utilized by the brain. It would be by this
mechanism that a body keeps the brain functioning at a
time of stress at the expense of other immediately "less
important" organs such as the skeletal muscle. However,
for optimal survival at some point post-stress it would still
be important to have some ability to move, and not have
all muscle fibers significantly depleted. Our work suggests
a model where FGFR1 would conserve a population of
muscle fibers during an atrophic phase for an unknown
period of time in order to allow some ability of post-stress
escape or movement. This sparing effect seemed to be spe-
cific for FGFR1, as RT-PCR analysis demonstrated no
change in FGFR4 expression in response to hind limb sus-
pension and FGFR2 and 3 are not expressed in adult skel-
etal muscle (data not shown). In cultured muscle, FGFR1
expression is typically associated with the proliferative
state of muscle, while FGFR4 expression is correlated with
the differentiated myofiber [50]. However, in muscle in
vivo the expression patterns of FGFR1 and FGFR4 are not
as clear cut. Satellite cells isolated from the Extensor digi-
torum longus and Soleus muscles differ in the expression
of FGF receptors. FGFR1 and R4 mRNA were strongly
expressed in proliferating cultures whereas in differentiat-
ing cultures, only FGFR1 was present in EDL satellite cells
while FGFR4 was also still expressed in Soleus cells. In
human muscle FGFR1 immunoreactivity has been dem-
onstrated in localized areas of myofibers [51]. These
observations, in addition to our work, add support to the
theory that FGFR1 regulation of a muscle fiber is much
more complex than simply regulating embryonic myob-
last differentiation.
We did not observe a localized accumulation of FGFR1 in
weight-bearing muscle as found in atrophying muscle.
However, we still found detectable mRNA for FGFR1. This
would suggest that FGFR1 can be expressed in and exert a
biological effect weight-bearing differentiated myofibers,
as it does in unloaded muscle fibers. The actual biological
effect of FGFR1 in weight bearing muscle would be less
clear. In our studies the ability of FGFR1 to regulate fiber
size only occurred during disuse atrophy, as ectopic
expression of FGFR1 in weighted muscle fibers stimulated
protein synthesis and degradation, but had no significant
phenotypic effect (See Figure 8). Even though there is no
direct effect on fiber size, it is possible that FGFR1 is stim-
ulating or involved in a fiber type conversion or recon-
struction. As mentioned above, FGFR1 expression is more
prevalent in fast muscles such as the EDL. This could
account for the increased degradation as the "old type"
proteins were being degraded in preparation for the
increased synthesis of the "new type" proteins/enzymes.
The effects of FGF signaling on fiber type conversion are
currently being examined.
Proposed role of FGFR1 in adult skeletal muscle Figure 8
Proposed role of FGFR1 in adult skeletal muscle. 
Increased production of FGFR1 in a weight bearing muscle 
fiber would result in an increase in protein synthesis and deg-
radation, which would counteract each other and result in no 
observable increase in muscle fiber size. However, in a fiber 
undergoing atrophy, increased FGFR1 would not elevate the 
significant amount of proteolysis that would already be 
occurring in an atrophying fiber. However, FGFR1 would still 
elevate protein synthesis in the atrophic fiber, thereby main-
taining fiber size and strength.
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It is known that FGFR signals via the Ras-Raf-MEK-MAPK
pathways. Activation of this pathway via acute up-regula-
tion of FGF-signaling promoted protein degradation in
differentiated muscle fibers from Caenorhabditis elegans
[52]. Our results confirm that this protein turnover regu-
lating property of FGFR is conserved in mammalian mus-
cle fibers and demonstrates a link between FGF signaling
and the ATP-dependent proteasome pathway. The fact
that FGFR1 activation of proteolyses in weight-bearing
muscle contrasts from its function in unloaded muscle
might simply be due to the fact that proteolysis is already
activated in unloaded muscle and overexpression of
FGFR1 can not exert any more of an effect on that process.
In summary, our results support a theory that FGFs play
crucial roles in regulation of postnatal skeletal muscle
maintenance. As the mechanisms regulating skeletal mus-
cle growth, atrophy, and hypertrophy are more clearly elu-
cidated, effective treatments for conditions resulting in a
loss of skeletal muscle function will be further developed.
The effects of FGFR1 noted in this study make this growth
factor receptor a strong candidate for future study of its
therapeutic or preventative potential.
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